Gelatin Tannate

Phase 1Small molecule

MMedical University of Warsaw

Gelatin Tannate is one of 21 small molecule programs targeting Gastroenteritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroenteritisActive, not recruiting

GastroenteritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

32 competitors in Gastroenteritis

#DrugCompanyPhaseTrials

Zofran

Novartis

Approved

8 2

Cipro

Bayer

Approved

—3

Reglan

IIstituto Clinico Humanitas

Approved

—4

Hyoscine-N-Butylbromide

Boehringer Ingelheim

Approved

2 5

Dimenhydrinate

SSt. Justine's Hospital

Approved

1 6

Rotarix ™

GSK

Phase 3

1 7

Domperidone

Johnson & Johnson

Phase 3

1 8

Prulifloxacin

Merck & Co.

Phase 3

1 9

Xolair

Roche

Phase 2

1 10

Papaverine

WWestern Galilee Hospital-Nahariya

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastroenteritis1 trial

Efficacy of Gelatin Tannate in Treatment Acute Gastroenteritis in Children.

Completed·MMedical University of Warsaw·Phase 1·NCT02280759·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gelatin Tannate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gelatin Tannate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gelatin Tannate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Warsaw company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMedical University of Warsaw

Gelatin Tannate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastroenteritis1 trial

References

Drug Info

Quick Facts

Related News